

AC220 Combination Study with Ara-C (overlapping administration)
MV411 Ara-C/AC220 Concurrent
Untreat
5% Cyclodextrin
AraC 30mkd qd / 5% Cyclodextrin
Saline / AC220 1mkd qd
AraC 30mkd qd /AC220 1mkd qd
Tumor volume (mm3)
3600
2600
1600
1500
1250
1000
750
500
250
0
5
15
25
35
45
55
65
75
85
95
105
115
Days post inoculation
AraC
AC220

FIG. 1



AC220 Combination Study with Ara-C (sequential administration)
MV411 Ara-C/AC220 Sequential
Untreat
5% Cyclodextrin
AraC 30 mkd qd / 5% Cyclodextrin
Saline / AC220 1 mkd qd
AraC 30 mkd qd / AC220 1 mkd qd
Tumor volume (mm3)
3600
2600
1600
1500
1250
1000
750
500
250
0
5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80
Days post Inoculation
AraC
AC220
AraC

FIG. 2



AC220 Combination Study with Aza-C (overlapping administration)
MV411 Aza-C/AC220 Concurrent
Untreat
5% Cyclodextrin
Aza-C 3 mkd qd / 5% Cyclodextrin
Aza-C 1 mkd qd / 5% Cyclodextrin
Saline / AC220 0.5 mkd qd
Aza-C 3 mkd qd / AC220 0.5 mkd qd
Aza-C 1 mkd qd / AC220 0.5 mkd qd
Flank tumor volume (mm3)
2500
2250
2000
1750
1500
1250
1000
750
500
250
0
12 17 22 27 32 37 42 47 52 57 62 67
Days post Inoculation
Aza-C
AC220

FIG.3



AC220 Combination Study with Aza-C (overlapping administration)
MV411 Aza-C/AC220 Sequential
Untreat
5% Cyclodextrin
Aza-C 3 mkd qd / 5% Cyclodextrin
Aza-C 1 mkd qd / 5% Cyclodextrin
Saline / AC220 0.5 mkd qd
Aza-C 3 mkd qd /AC220 0.5 mkd qd
Aza-C 1 mkd qd /AC220 0.5 mkd qd
Flank tumor volume (mm3)
2500
2250
2000
1750
1500
1250
1000
750
500
250
0
12 17 22 27 32 37 42 47 52 57 62 67
Days post Inoculation
Aza-C
AC220

FIG.4



Etoposide concurrent AC220_MV411_72hr_n=4 duplicates
AC220 : Etoposide
Mix1 (0.0875:34.57)
Mix2 (0.175:34.57)
Mix3 (0.35:34.57)
Mix4 (0.7:34.57)
Average Combination index
3.8
3.6
3.4
3.2
3.0
2.8
2.6
2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Antagonize
Additive
Synergy
ED10
ED25
ED50
ED75
ED90
ED95
Fraction of Inhibition

FIG.5A



Etoposide 1 day before AC220_MV411_72hr_n=2 duplicates
AC220 : Etoposide
Mix1 (0.0875:34.57)
Mix2 (0.175:34.57)
Mix3 (0.35:34.57)
Mix4 (0.7:34.57)
Average Combination index
5.0
4.8
4.6
4.4
4.2
4.0
3.8
3.6
3.4
3.2
3.0
2.8
2.6
2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Antagonize
Additive
Synergy
ED10
ED25
ED50
ED75
ED90
ED95
Fraction of Inhibition

FIG.5B



Daunomycin concurrent AC220_MV411_72hr_n=3 duplicates
AC220 : Daunomycin
Mix1 (0.0875:12.65)
Mix2 (0.175:12.65)
Mix3 (0.35:12.65)
Mix4 (0.7:12.65)
Average Combination index
3.8
3.6
3.4
3.2
3.0
2.8
2.6
2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Antagonize
Additive
Synergy
ED10
ED25
ED50
ED75
ED90
ED95
Fraction of Inhibition

FIG.6A



Daunomycin 1day before AC220_MV411_72hr total_n=2 duplicates
AC220 : Daunomycin
Mix1 (0.0875:12.65)
Mix2 (0.175:12.65)
Mix3 (0.35:12.65)
Mix4 (0.7:12.65)
Average Combination index
3.8
3.6
3.4
3.2
3.0
2.8
2.6
2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Antagonize
Additive
Synergy
ED10
ED25
ED50
ED75
ED90
ED95
Fraction of Inhibition

FIG.6B



Daunomycin 1day after AC220_MV411_72hr total_n=3 duplicates
AC220 : Daunomycin
Mix1 (0.0875:12.65)
Mix2 (0.175:12.65)
Mix3 (0.35:12.65)
Mix4 (0.7:12.65)
Average Combination index
3.8
3.6
3.4
3.2
3.0
2.8
2.6
2.4
2.2
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Antagonize
Additive
Synergy
ED10
ED25
ED50
ED75
ED90
ED95
Fraction of Inhibition

FIG.6C



1 Untreated
2 Vehicle
3 Dauno 1.5 mkd
4 Dauno 3.0 mkd
5 AC220 0.5 mkd
6 Dauno 1.5 mkd + AC220 0.5 mkd
7 Dauno 3.0 mkd + AC220 0.5 mkd
8 Dauno 1.5 mkd / AC200 0.5 mkd
9 Dauno 3.0 mkd / AC220 0.5 mkd
Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100
Days post Inoculation

FIG. 7